Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 3
1977 4
1978 2
1979 2
1980 4
1981 3
1982 9
1983 9
1984 9
1985 3
1986 3
1987 8
1988 3
1990 10
1991 7
1992 5
1993 14
1994 13
1995 2
1996 10
1997 6
1998 7
1999 11
2000 6
2001 7
2002 8
2003 14
2004 14
2005 10
2006 22
2007 22
2008 23
2009 18
2010 17
2011 7
2012 7
2013 2
2014 1
2015 1
2016 1
2020 2
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

318 results

Results by year

Filters applied: . Clear all
Page 1
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Motzer RJ, et al. Among authors: bukowski rm. N Engl J Med. 2007 Jan 11;356(2):115-24. doi: 10.1056/NEJMoa065044. N Engl J Med. 2007. PMID: 17215529 Free article. Clinical Trial.
Pazopanib.
Bukowski RM, Yasothan U, Kirkpatrick P. Bukowski RM, et al. Nat Rev Drug Discov. 2010 Jan;9(1):17-8. doi: 10.1038/nrd3073. Nat Rev Drug Discov. 2010. PMID: 20043026
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. Heng DY, et al. Among authors: bukowski rm. J Clin Oncol. 2009 Dec 1;27(34):5794-9. doi: 10.1200/JCO.2008.21.4809. Epub 2009 Oct 13. J Clin Oncol. 2009. PMID: 19826129
Temsirolimus: a safety and efficacy review.
Bukowski RM. Bukowski RM. Expert Opin Drug Saf. 2012 Sep;11(5):861-79. doi: 10.1517/14740338.2012.713344. Epub 2012 Aug 6. Expert Opin Drug Saf. 2012. PMID: 22861825 Review.
Novel drugs for renal cell carcinoma.
Vakkalanka BK, Bukowski RM. Vakkalanka BK, et al. Among authors: bukowski rm. Expert Opin Investig Drugs. 2008 Oct;17(10):1501-16. doi: 10.1517/13543784.17.10.1501. Expert Opin Investig Drugs. 2008. PMID: 18808310 Review.
Carcinoid myopathy.
Lederman RJ, Bukowski RM, Nickerson P. Lederman RJ, et al. Among authors: bukowski rm. Cleve Clin J Med. 1987 Jul-Aug;54(4):299-303. doi: 10.3949/ccjm.54.4.299. Cleve Clin J Med. 1987. PMID: 3652434 Free article. No abstract available.
Therapy of thrombotic thrombocytopenic purpura: an overview.
Bukowski RM, Hewlett JS, Reimer RR, Groppe CW, Weick JK, Livingston RB. Bukowski RM, et al. Semin Thromb Hemost. 1981 Winter;7(1):1-8. doi: 10.1055/s-2007-1005062. Semin Thromb Hemost. 1981. PMID: 6165085 Review. No abstract available.
Targeted therapy for metastatic renal cell carcinoma.
Motzer RJ, Bukowski RM. Motzer RJ, et al. Among authors: bukowski rm. J Clin Oncol. 2006 Dec 10;24(35):5601-8. doi: 10.1200/JCO.2006.08.5415. J Clin Oncol. 2006. PMID: 17158546 Review.
Biomarkers in clear cell renal cell carcinoma.
George S, Bukowski RM. George S, et al. Among authors: bukowski rm. Expert Rev Anticancer Ther. 2007 Dec;7(12):1737-47. doi: 10.1586/14737140.7.12.1737. Expert Rev Anticancer Ther. 2007. PMID: 18062748 Review.
318 results